Cell X Technologies and Aspen Neuroscience have joined forces in a groundbreaking collaboration to address the critical challenges of throughput and scalability in the manufacturing of cell-based therapies.
The partnership aims to automate the complex process of iPSC (induced pluripotent stem cell) production using Celligent™ technology, a platform that combines advanced robotics, machine learning (ML), and deep learning (DL) to optimize cell processing.
This collaboration is a major step forward for Aspen Neuroscience’s mission to develop personalized cell-replacement therapies for Parkinson’s disease.
By utilizing automated biomanufacturing systems, the partnership intends to create a scalable, efficient solution that addresses the unmet medical needs of patients suffering from Parkinson’s and potentially other diseases.
The Celligent™ platform is designed to reduce dependency on human operators, providing greater precision and efficiency in cell selection through adaptive process control.
This could revolutionize the GMP-compliant manufacturing process for autologous and allogeneic therapies, as well as open new avenues for tissue engineering and artificial organ applications.
This collaboration highlights the growing importance of automation in biotech, particularly in personalized medicine, and underscores the commitment of both companies to advancing autologous regenerative therapies for a wide range of conditions.
By leveraging cutting-edge AI-driven solutions, this partnership between Cell X Technologies and Aspen Neuroscience may redefine the future of cell therapy, bringing faster, more scalable treatments to patients in need.